Artificially manipulated immune cell
AssigneeToolgen Incorporated
InventorsSeok Joong Kim, Yoon-Young Kim, Ho-Sung Yu, In-Young Jung, Jung Min Lee
Life of this patent
Estimating the term…
Abstract
The presents invention relates to a composition for manipulating an immune cell which is used for artificially manipulating an immune cell. More particularly, the present invention relates to a composition for manipulating an immune cell which is used for artificially manipulating an immune cell and a manipulated immune cell comprising an artificially modified immunity regulating gene and an artificial receptor which is produced using the composition, and use thereof.
Claims13
A manipulated human T cell with an enhanced immune activity comprising:
- an engineered genome comprising an engineered endogenous DGKA gene and an engineered endogenous DGKZ gene;
- and
- at least one artificial receptor and/or nucleic acid encoding the artificial receptor,
- wherein the engineered endogenous DGKA gene comprises a first artificial modification,
- wherein the first artificial modification is a first indel by CRISPR/Cas gene editing and induced in a region of exon 7 of the wild-type DGKA gene, wherein the engineered endogenous DGKA gene does not comprise any further modification other than the first artificial modification,
- wherein the engineered endogenous DGKZ gene comprises a second artificial modification,
- wherein the second artificial modification is a second indel by CRISPR/Cas gene editing and induced in a region of exon 3 of the wild-type DGKZ gene, wherein the engineered endogenous DGKZ gene does not comprise any further modification other than the second artificial modification,
- wherein the first artificial modification causes at least one of a reduced expression of engineered endogenous DGKA gene and a functional impairment of the protein expressed from the engineered endogenous DGKA gene, and the second artificial modification causes at least one of a reduced expression of engineered endogenous DGKZ gene and a functional impairment of the protein expressed from the engineered endogenous DGKZ gene, in a manner that the manipulated human T cell has the enhanced immune activity.
A composition for immunotherapy comprising a manipulated human T cell with an enhanced immune activity, wherein the manipulated human T cell comprises:
- an engineered genome comprising an engineered endogenous DGKA gene and engineered endogenous DGKZ gene;
- and
- at least one artificial receptor and/or nucleic acid encoding the artificial receptor,
- wherein the engineered endogenous DGKA gene comprises a first artificial modification,
- wherein the first artificial modification is a first indel by CRISPR/Cas gene editing and induced in a region of exon 7 of the wild-type DGKA gene, wherein the engineered endogenous DGKA gene does not comprise any further modification other than the first artificial modification,
- wherein the engineered endogenous DGKZ gene comprises a second artificial modification,
- wherein the second artificial modification is a second indel and induced in a region of exon 3 of the wild-type DGKZ gene, wherein the engineered endogenous DGKZ gene does not comprise any further modification other than the second artificial modification,
- wherein the first artificial modification causes at least one of a reduced expression of engineered endogenous DGKA gene and a functional impairment of the protein expressed from the engineered endogenous DGKA gene, and the second artificial modification causes at least one of a reduced expression of engineered endogenous DGKZ gene and a functional impairment of the protein expressed from the engineered endogenous DGKZ gene, in a manner that the manipulated human T cell has the enhanced immune activity.
Dependencies are inferred from the claim text.